Although the number of GLP-1 receptor agonist prescriptions are rapidly increasing, the data on overdose of these agents are limited. This is particularly important given the high incidence of online procurement of these drugs, which raises questions of quality control and risk of design errors. This is a retrospective chart review of national registry and poison center data to evaluate supratherapeutic exposures to GLP-1 receptor agonists (e.g semaglutide, tirzepatide) which aims to evaluate: the following research questions:
Does the magnitude of supratherapeutic GLP-1 receptor agonist (GLP1-RA) dosing errors impact adverse effect profile or clinical outcomes (treatment, disposition, hospital length of stay)?
Does the type of GLP-1 RA impact adverse effect profile or clinical outcomes (treatment, disposition, hospital length of stay)?
Does the source of GLP-RA (pharmacy via online or "alternative" retailer) impact adverse effect profile or clinical outcomes (treatment, disposition, hospital length of stay)?
Students/residents can assist with development of data collection tools, data abstraction from poison center charts, and abstract writing. There are some team meetings, but most work can be done asynchronously/remotely.
*** The goal for this project is for the preliminary data abstraction to be done by November 2025**